Big Pharma M&A set for mega year as patent expiries drive deal urgency

• Over $300 billion in pharmaceutical revenue faces loss of exclusivity in the next five years, with Merck's Keytruda (over half its revenue) losing patent protection in 2028
• Eli Lilly, Gilead, and Merck have been the biggest spenders, with Lilly alone deploying over $35 billion through April 29, fueled by strong cash reserves of $7.27 billion
• Mid-size deals under $10 billion dominate as companies make multiple bets focusing on oncology, obesity, cardiovascular disease, and AI-driven drug discovery to offset impending patent cliffs

Summary: Big Pharma M&A Poised for Record Year Amid Patent Cliff Pressures

Biotech M&A activity is surging in 2026, driven by looming patent expirations threatening major pharmaceutical revenues. First-quarter deal value reached $84 billion, nearly double the $44.4 billion recorded in the prior year period, marking the strongest start since 2019.

Key Drivers:

If current momentum continues, 2026 total biopharma M&A could exceed $250 billion—second only to 2019's record $328 billion. Multiple factors are fueling dealmaking: deep cash reserves, attractive biotech valuations, newly approved drugs, and reduced regulatory uncertainty alongside the critical patent cliff urgency.

Patent Expiration Crisis:

Over $300 billion in sector revenue faces loss of exclusivity (LOE) within five years. Major drugs at risk include Merck's Keytruda (losing exclusivity in 2028), which generates over half the company's revenue. Eli Lilly, Gilead, Bristol Myers Squibb, and Pfizer also face blockbuster patent losses. Bernstein analysts note future revenue exposed to patent expiry is 2.5 times higher than the past 16 years.

Major Players:

Eli Lilly leads acquisition spending with over $35 billion deployed through April 29, followed by Gilead Sciences and Merck. Lilly ended 2025 with $7.27 billion in cash reserves. Recent CEO changes at GSK and Novo Nordisk have coincided with more aggressive M&A strategies.

Deal Characteristics:

Mid-size deals under $10 billion dominate, with companies making multiple bets to spread risk. Target areas include oncology, immunology, neurology, cardiovascular disease, and obesity treatments. AI-enabled drug discovery companies are emerging as preferred acquisition targets due to accelerated development timelines.

Industry experts characterize the activity as buyers "buying time" rather than optionality, reflecting strategic anxiety over diminishing portfolios.